ID   HS-SY-2
AC   CVCL_8719
SY   HS-SY-II; HSSY-II; HSSYII; HSSY2; Hiroshi Sonobe-SYnovial-2
DR   BTO; BTO:0006086
DR   CLO; CLO_0050072
DR   BioSample; SAMN03472029
DR   cancercelllines; CVCL_8719
DR   Cosmic; 1217465
DR   Cosmic; 1319811
DR   Cosmic; 2307724
DR   DepMap; ACH-002085
DR   GEO; GSM482569
DR   GEO; GSM1676333
DR   GEO; GSM1701665
DR   GEO; GSM2887618
DR   GEO; GSM2887619
DR   Progenetix; CVCL_8719
DR   RCB; RCB2231
DR   Wikidata; Q54896293
RX   PubMed=1331610;
RX   PubMed=7539744;
RX   PubMed=7736791;
RX   PubMed=24726063;
RX   PubMed=26351324;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~60 hours (PubMed=1331610).
CC   Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=1331610; PubMed=7539744).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: HS-SY-11; Note=Occasionally.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 10
ST   D16S539: 9
ST   D5S818: 10,12
ST   D7S820: 10,12
ST   TH01: 8
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C6534; Monophasic synovial sarcoma
DI   ORDO; Orphanet_3273; Synovial sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=1331610;
RA   Sonobe H., Manabe Y., Furihata M., Iwata J., Oka T., Ohtsuki Y.,
RA   Mizobuchi H., Yamamoto H., Kumano O., Abe S.;
RT   "Establishment and characterization of a new human synovial sarcoma
RT   cell line, HS-SY-II.";
RL   Lab. Invest. 67:498-505(1992).
//
RX   PubMed=7539744; DOI=10.1002/j.1460-2075.1995.tb07228.x;
RA   Crew A.J., Clark J., Fisher C., Gill S., Grimer R., Chand A.,
RA   Shipley J.M., Gusterson B.A., Cooper C.S.;
RT   "Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with
RT   homology to the Kruppel-associated box in human synovial sarcoma.";
RL   EMBO J. 14:2333-2340(1995).
//
RX   PubMed=7736791; DOI=10.1159/000133992;
RA   Renwick P.J., Reeves B.R., Dal Cin P.S., Fletcher C.D.M., Kempski H.,
RA   Sciot R., Kazmierczak B., Jani K., Sonobe H., Knight J.C.;
RT   "Two categories of synovial sarcoma defined by divergent chromosome
RT   translocation breakpoints in Xp11.2, with implications for the
RT   histologic sub-classification of synovial sarcoma.";
RL   Cytogenet. Cell Genet. 70:58-63(1995).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//